公开(公告)号：US10766966B2

公开(公告)日：2020-09-08

申请号：US15517991

申请日：2015-10-09

Applicant: INNATE PHARMA

Inventor： Ivan Perrot ,  Carine Paturel ,  Laurent Gauthier

IPC: C07K16/00 ,  C07K16/28 ,  C07K16/40 ,  C07K16/30

Abstract: This disclosure relates to antibodies that bind an epitope present on CD73 expressed at the surface of cells, including tumor cells, and that inhibit the enzymatic (ecto-5′ nucleotidase) activity of the CD73 enzyme. Such agents can be used for the treatment of diseases such as cancers.

公开(公告)号：US10675359B2

公开(公告)日：2020-06-09

申请号：US15702586

申请日：2017-09-12

Applicant: Innate Pharma ,  Paul Scherrer Institut

Inventor： Patrick Dennler ,  Delphine Bregeon ,  Laurent Gauthier ,  François Romagné ,  Christian Belmant ,  Eliane Fischer ,  Roger Schibli

IPC: A61K47/68 ,  C07K16/00 ,  A61K47/60 ,  C07C217/08 ,  C07C223/02 ,  C07C229/26 ,  C07C233/62 ,  C07C247/04 ,  C07C323/12 ,  C07C323/60 ,  C07D225/08 ,  C07D257/08 ,  C07D277/06 ,  C07F9/50 ,  C07K19/00 ,  C12N9/10 ,  C12P21/00 ,  G01N33/68

Abstract: The present application relates to methods for the functionalization of immunoglobulins, in particular with drugs. Also disclosed herein are linking reagents, functionalized antibodies, pharmaceutical compositions, and method of treating disease and/or conditions.

公开(公告)号：US10577416B2

公开(公告)日：2020-03-03

申请号：US14377274

申请日：2013-02-07

Applicant: INNATE PHARMA, S.A.

Inventor： Mathieu Blery ,  Laurent Gauthier ,  Ivan Perrot ,  Cecile Bonnafous

IPC: C07K16/28 ,  A61K39/00 ,  G01N33/569

Abstract: The present invention relates to methods for the treatment of disorders mediated by MICA-expressing cells using antibodies, antibody fragments, and derivatives thereof that specifically bind MICA. The invention also relates to antibodies; cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; and pharmaceutical compositions comprising the same.

公开(公告)号：US20180193476A1

公开(公告)日：2018-07-12

申请号：US15702586

申请日：2017-09-12

Applicant: Innate Pharma ,  Paul Scherrer Institut

Inventor： Patrick Dennler ,  Delphine Bregeon ,  Laurent Gauthier ,  François Romagné ,  Christian Belmant ,  Eliane Fischer ,  Roger Schibli

IPC: A61K47/68 ,  G01N33/68 ,  C12N9/10 ,  C12P21/00 ,  C07K19/00 ,  C07K16/00 ,  C07F9/50 ,  C07D277/06 ,  C07D257/08 ,  C07D225/08 ,  C07C323/60 ,  C07C323/12 ,  C07C247/04 ,  C07C233/62 ,  C07C229/26 ,  C07C223/02 ,  C07C217/08

Abstract: The present application relates to methods for the functionalization of immunoglobulins, in particular with drugs. Also disclosed herein are linking reagents, functionalized antibodies, pharmaceutical compositions, and method of treating disease and/or conditions.

公开(公告)号：US20180071402A1

公开(公告)日：2018-03-15

申请号：US15654585

申请日：2017-07-19

Applicant: Innate Pharma ,  Paul Scherrer Institut

Inventor： Delphine Bregeon ,  Patrick Dennler ,  Christian Belmant ,  Eliane Fischer ,  Laurent Gauthier ,  Francois Romagné ,  Roger Schibli

IPC: G01N33/68 ,  C12N9/10 ,  C12P21/00 ,  C07K19/00 ,  C07K16/00 ,  C07F9/50 ,  C07D277/06 ,  C07D257/08 ,  C07D225/08 ,  C07C323/60 ,  C07C323/12 ,  C07C247/04 ,  C07C233/62 ,  C07C229/26 ,  C07C223/02 ,  C07C217/08

CPC classification number: A61K47/6803 ,  A61K47/60 ,  A61K47/68 ,  A61K47/6807 ,  A61K47/6813 ,  A61K47/6817 ,  A61K47/6865 ,  A61K47/6871 ,  C07C217/08 ,  C07C223/02 ,  C07C229/26 ,  C07C233/62 ,  C07C247/04 ,  C07C323/12 ,  C07C323/60 ,  C07D225/08 ,  C07D257/08 ,  C07D277/06 ,  C07F9/5022 ,  C07K16/00 ,  C07K19/00 ,  C07K2317/40 ,  C12N9/1044 ,  C12P21/005 ,  G01N33/6854

Abstract: The present application relates to methods for the functionalization of immunoglobulins, in particular with drugs. Also disclosed herein are linking reagents, functionalized antibodies, pharmaceutical compositions, and method of treating disease and/or conditions.

公开(公告)号：US20160347853A1

公开(公告)日：2016-12-01

申请号：US15204851

申请日：2016-07-07

Applicant: Innate Pharma

Inventor： Laurent Gauthier ,  Catherine Massacrier ,  Yannis Morel ,  Carine Paturel

IPC: C07K16/28 ,  A61K45/06 ,  A61K47/48 ,  A61K39/395

CPC classification number: C07K16/2896 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/6849 ,  C07K2317/34 ,  C07K2317/35 ,  C07K2317/54 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92

Abstract: The present invention relates to antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind TLR3, and that optionally further modulate, e.g. inhibit, signaling. The invention also relates to cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same; methods of using the antibodies to diagnose, treat or prevent diseases, e.g. autoimmune diseases, inflammatory diseases and the like.

Abstract translation: 本发明涉及特异性结合TLR3的抗体（例如单克隆抗体），抗体片段及其衍生物，并且任选进一步调节，例如， 抑制信号。 本发明还涉及产生这种抗体的细胞; 制备此类抗体的方法; 抗体的片段，变体和衍生物; 包含它们的药物组合物; 使用抗体诊断，治疗或预防疾病的方法，例如， 自身免疫性疾病，炎症性疾病等。

公开(公告)号：US08981065B2

公开(公告)日：2015-03-17

申请号：US13936486

申请日：2013-07-08

Applicant: Novo Nordisk A/S—Novo Alle ,  Innate Pharma S.A.S. ,  University of Genoa

Inventor： Alessandro Moretta ,  Mariella Della Chiesa ,  Pascale Andre ,  Laurent Gauthier ,  Francois Romagne ,  Peter Andreas Nicolai Reumert Wagtmann ,  Ivan Svendsen ,  Stefan Zahn ,  Anders Svensson ,  Matthias Thorolfsson ,  Soren Berg Padkaer ,  Kristian Kjaergaard ,  Pieter Johannes Louis Spee ,  Michael Wilken

IPC: C12P21/08 ,  C07K16/00 ,  C07K16/28

CPC classification number: C07K16/42 ,  C07K16/28 ,  C07K16/2803 ,  C07K2299/00 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.

Abstract translation: 描述了用于调节受试者的免疫应答的组合物和方法。 更具体地，描述了调节NK细胞活性并允许在哺乳动物受试者中增强NK细胞细胞毒性的人抗体，以及具有与人单克隆抗体1-7F9或1-4F1类似的抗原结合特性的抗体。 还描述了这种抗体的片段和衍生物，以及包含其的药物组合物及其用途，特别是用于治疗，以增加受试者的NK细胞活性或细胞毒性。

公开(公告)号：US20140356385A1

公开(公告)日：2014-12-04

申请号：US14367840

申请日：2012-12-21

Applicant: Innate Pharma ,  Paul Scherrer Institut

Inventor： Patrick Dennler ,  Delphine Bregeon ,  Laurent Gauthier ,  François Romagné ,  Christian Belmant ,  Eliane Fischer ,  Roger Schibli

IPC: A61K47/48 ,  C07K16/00

CPC classification number: A61K47/6803 ,  A61K47/60 ,  A61K47/68 ,  A61K47/6807 ,  A61K47/6813 ,  A61K47/6817 ,  A61K47/6865 ,  A61K47/6871 ,  C07C217/08 ,  C07C223/02 ,  C07C229/26 ,  C07C233/62 ,  C07C247/04 ,  C07C323/12 ,  C07C323/60 ,  C07D225/08 ,  C07D257/08 ,  C07D277/06 ,  C07F9/5022 ,  C07K16/00 ,  C07K19/00 ,  C07K2317/40 ,  C12N9/1044 ,  C12P21/005 ,  G01N33/6854

Abstract: The present application relates to methods for the functionalization of immunoglobulins, in particular with drugs. Also disclosed herein are linking reagents, functionalized antibodies, pharmaceutical compositions, and method of treating disease and/or conditions.

Abstract translation: 本申请涉及用于免疫球蛋白功能化的方法，特别是与药物。 本文还公开了连接试剂，官能化抗体，药物组合物和治疗疾病和/或病症的方法。

公开(公告)号：US11623954B2

公开(公告)日：2023-04-11

申请号：US16629588

申请日：2018-07-09

Applicant: INNATE PHARMA

Inventor： Stéphanie Cornen ,  Benjamin Rossi ,  Nicolai Wagtmann ,  Laurent Gauthier

IPC: C07K16/28 ,  A61K39/00

Abstract: This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers or infectious disease.

公开(公告)号：US11130817B2

公开(公告)日：2021-09-28

申请号：US15767661

申请日：2016-10-11

Applicant: INNATE PHARMA ,  CENTRE LEON BERARD

Inventor： Christophe Caux ,  Laurent Gauthier ,  Nicolas Gourdin ,  Christine Menetrier-Caux ,  Carine Paturel ,  Ivan Perrot

IPC: C07K16/28 ,  C07K16/40 ,  A61P35/00

Abstract: Provided are antibodies that bind and inhibit CD73, are capable of increasing the proliferation of T cells in the presence of CD39-expressing B cells and ATP. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent cancer.